Last $58.11 USD
Change Today -0.32 / -0.55%
Volume 6.3M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 8:04 PM 07/23/14 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$58.30
Previous Close
$58.43
Day High
$58.50
Day Low
$58.05
52 Week High
05/1/14 - $59.84
52 Week Low
11/1/13 - $44.62
Market Cap
169.8B
Average Volume 10 Days
7.1M
EPS TTM
$3.48
Shares Outstanding
2.9B
EX-Date
09/11/14
P/E TM
16.7x
Dividend
$1.76
Dividend Yield
3.01%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The company’s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of cardiovascular, diabetes and obesity, respiratory, women's health and endocrine, inflammatory and infectious diseases, oncology, ophthalmology, immunology, infectious diseases, and others. This segment also provides vaccines, including preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products comprising vaccines, antibiotics, and anti-inflammatory drugs for respiratory diseases, as well as products for the treatment of fertility disorders. The company’s Consumer Care segment develops, manufactures, and sells over-the-counter products consisting of non-drowsy antihistamines; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant sprays; and products for occasional constipation, frequent heartburn, and overactive bladder in women; foot care products, including topical antifungal, and foot and sneaker odor/wetness products; and sun care products, such as sun care lotions, sprays, and dry oils. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, food chain and mass merchandiser outlets, club stores, and specialty channels, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. It has collaborations with AstraZeneca LP, Pfizer Inc., Samsung Bioepis Co., Ltd., Sanofi Pasteur S.A., and Sysmex Inostics GmbH. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

77,300 Employees
Last Reported Date: 02/27/14
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
Executive Vice President and President of Glo...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Merck and Pharmstandard OJSC Enters Partnership Agreement for Production, Distribution and Marketing of Rebif

Merck and Pharmstandard OJSC concluded a number of partnership agreements aimed at long-term collaboration in the field of production, distribution and marketing of Rebif. Production of the medicine will be done at Pharmstandard-UfaVITA plant in Ufa. Rebif is used as first-line MS therapy according to international standards for MS treatment. Ministry of Health of Russian Federation has been purchasing interferon beta-1a and particularly Rebif for MS patients within 7 Nozologies program during last several years. Approximately 15% of patients with relapsing-remitting MS who are indicated for medical treatment receive Rebif. Thanks to the production localization in RF Rebif will become more accessible for this patients' category. In October 2013 localized Rebif was registered by Ministry of Health of Russian Federation and Pharmstandard-UfaVITA OJSC was approved as production facility for secondary packaging, quality control and release to the market of the medicine. Within the course of 2013, both companies were undergoing the process of transfer of analytical methods for production. The process took approximately 9 months. And was finalized by "Technological transfer Protocol" signing. This is the first time in Merck history that company transferred rights for production, quality control and marketing of biotechnological medicine to a third party. Cooperation between Pharmstandard and Merck began in July 2012, when a decision to implement secondary packaging of Rebif was made. In addition to the secondary packaging Pharmstandard carries out quality control of the finished products. Nowadays an active process of methodology transfer for fill&finish production was started. It is anticipated that the full production cycle will be launched in the fourth quarter of 2015. Marketing support of Rebif drug in Russia will be carried out by Pharmstandard.

Merck Announces Data from Investigational Phase 3 Study on EMEND

Merck announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND(R) (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. In this study in pediatric cancer patients undergoing very highly, highly, or moderately emetogenic (vomit-inducing) chemotherapy, the use of the EMEND regimen for CINV prevention was significantly more effective than a control regimen in achieving Complete Response, defined as no vomiting or retching and no use of rescue medication for nausea and vomiting, in all phases of CINV (acute, delayed, and overall). These new data were presented in an oral session at the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) Annual International Symposium on Supportive Care in Cancer. Merck plans worldwide regulatory submissions for EMEND (aprepitant), beginning in the United States, for use in the prevention of CINV in pediatric and adolescent cancer patients (ages 6 months to 17 years). In the United States, Merck plans to submit a New Drug Application (NDA) for a new pediatric formulation (powder for suspension) and a supplemental NDA for use of the current formulation (capsules). Both filings are planned for the second half of 2014.

Merck Announces European Medicines Agency Accepted for Review a Marketing Authorization Application for Pembrolizumab (MK-3475)

Merck announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the company's investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Additional regulatory filings in other countries outside of Europe are planned by the end of 2014. Pembrolizumab (MK-3475) is an investigational, selective, humanized, monoclonal anti-PD-1 antibody designed to reactivate anti-tumor immunity. Pembrolizumab exerts dual ligand blockade of the PD-1 pathway by inhibiting the interaction of PD-1 on T cells with its ligands PD-L1 and PD-L2.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $58.11 USD -0.32

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.68 USD -0.44
Bayer AG €100.29 EUR +0.54
GlaxoSmithKline PLC 1,482 GBp -73.50
L'Oreal SA €128.65 EUR +0.40
Sanofi €76.93 EUR -0.06
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 38.5x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 37.8x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.